Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients

We aimed to identify microRNA (miRNA) expression patterns in the serum of prostate cancer (CaP) patients that predict the risk of early treatment failure following radical prostatectomy (RP). Microarray and Q-RT-PCR analyses identified 43 miRNAs as differentiating disease stages within 14 prostate c...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2014-02, Vol.5 (3), p.824-840
Main Authors: Singh, Prashant K, Preus, Leah, Hu, Qiang, Yan, Li, Long, Mark D, Morrison, Carl D, Nesline, Mary, Johnson, Candace S, Koochekpour, Shahriar, Kohli, Manish, Liu, Song, Trump, Donald L, Sucheston-Campbell, Lara E, Campbell, Moray J
Format: Article
Language:English
Subjects:
Cell Line, Tumor
Disease Progression
Epigenomics
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Male
MicroRNAs - biosynthesis
MicroRNAs - blood
MicroRNAs - genetics
Predictive Value of Tests
Proportional Hazards Models
Prostatic Neoplasms - blood
Prostatic Neoplasms - genetics
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - therapy
Research Paper
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to identify microRNA (miRNA) expression patterns in the serum of prostate cancer (CaP) patients that predict the risk of early treatment failure following radical prostatectomy (RP). Microarray and Q-RT-PCR analyses identified 43 miRNAs as differentiating disease stages within 14 prostate cell lines and reflectedpublically available patient data. 34 of these miRNA were detectable in the serum of CaP patients. Association with time to biochemical progression was examined in a cohort of CaP patients following RP. A greater than two-fold increase in hazard of biochemical progression associated with altered expression of miR-103, miR-125b and miR-222 (p
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.1776